Extended network menu
Everything else our partners can run
The standing catalogue holds the 42 tests set up for routine ordering. Behind it sits a much wider menu — 648 further assays across our partner laboratories, from esoteric clinical pathology to disease-focused genomic panels.
These are available on request, not from the shelf. Anything on this page has to be quoted and set up before a first order — turnaround, specimen requirements, and shipping are confirmed case by case. Send us the clinical question and we will tell you whether the pathway is workable.
481 assays
GC Labs
Clinical areas AC can route to GC Labs, grouped as the laboratory organises them.
Infectious Disease
98 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Adenovirus Antigen | AC-GCL-B108 | DIFA (Direct immunofluorescent assay) | ~9 days |
| Anti-tuberculosis drug resistance mutation (Isoniazid) [Sequencing] | AC-GCL-M338 | Sanger sequencing | ~15 days |
| Anti-tuberculosis drug resistance mutation (Rifampicin) [Sequencing] | AC-GCL-M337 | Sanger sequencing | ~15 days |
| Antifungal susceptibility testing | AC-GCL-B337 | MIC (Minimum inhibitory concentration) | ~10 days |
| Antimicrobial susceptibility testing | AC-GCL-B405 | MIC (Minimum inhibitory concentration) | ~11 days |
| Antimicrobial susceptibility testing (multidrug resistance) | AC-GCL-Q565 | MIC (Minimum inhibitory concentration) | ~11 days |
| Antistrep-O (ASO, Quantitative) | AC-GCL-S831 | TIA (Turbidimetric immunoassay) | ~8 days |
| Antitubercular drugs resistance (INH) | AC-GCL-B154 | PCR with hybridization | ~13 days |
| Antitubercular drugs resistance (INH/RFP) | AC-GCL-K079 | PCR with hybridization | ~13 days |
| Antitubercular drugs resistance (RFP) | AC-GCL-B153 | PCR with hybridization | ~13 days |
| Aspergillus (galactomannan) Ag | AC-GCL-Z004 | EIA (Enzyme immunoassay) | ~9 days |
| Aspergillus fumigatus IgG | AC-GCL-X149 | FEIA (Fluorescence enzyme immunoassay) | ~10 days |
| BK virus (Quantitative) [P, Real-time PCR] | AC-GCL-X233 | Real-time PCR | ~10 days |
| BK virus (Quantitative) [RU, Real-time PCR] | AC-GCL-X231 | Real-time PCR | ~10 days |
| BK virus detection [Real-time PCR] | AC-GCL-K084 | PCR (Polymerase chain reaction) | ~10 days |
| Bordetella pertussis [Real-time PCR] | AC-GCL-K083 | Real-time PCR | ~8 days |
| C. difficile toxin A & B [Real-time PCR] | AC-GCL-N114 | Real-time PCR | ~10 days |
| Candida albicans PCR | AC-GCL-N304 | PCR (Polymerase chain reaction) | ~8 days |
| Chlamydia pneumoniae IgG | AC-GCL-S789 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Chlamydia pneumoniae IgM | AC-GCL-S790 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Chlamydia pneumoniae PCR | AC-GCL-S678 | PCR (Polymerase chain reaction) | ~8 days |
| Chlamydia trachomatis Ab IgG | AC-GCL-S881 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Chlamydia trachomatis Ab IgM | AC-GCL-S882 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Clarithromycin resistance test | AC-GCL-N225 | PCR (Polymerase chain reaction) | ~8 days |
| Clonorchis sinensis Ab, IgG | AC-GCL-X881 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Clostridioides difficile toxin A,B | AC-GCL-B164 | ELFA (Enzyme linked fluorescent assay) | ~9 days |
| CRE genotyping (GeneXpert) | AC-GCL-W981 | Real-time PCR | ~9 days |
| Cysticercosis Ab IgG | AC-GCL-X883 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Dengue virus [Real-time RT-PCR] | AC-GCL-N996 | Real-time RT-PCR | ~8 days |
| Enterovirus [Real-time RT-PCR] | AC-GCL-S588 | Real-time RT-PCR | ~8 days |
| Gastrointestinal Pathogen bacteria Panel [Multiplex PCR] | AC-GCL-G221 | Multiplex PCR | ~8 days |
| Gastrointestinal Pathogen virus Panel [Multiplex real-time PCR] | AC-GCL-G210 | Multiplex real-time RT-PCR | ~8 days |
| Genitourinary tract infection & Sexually transmitted infection panel, PCR | AC-GCL-L735 | Multiplex real-time PCR | ~8 days |
| Haemophilus ducreyi PCR | AC-GCL-M727 | PCR (Polymerase chain reaction) | ~8 days |
| Hantaan & Seoul virus PCR | AC-GCL-S928 | RT-nested PCR | ~10 days |
| Hantaan virus Ab | AC-GCL-S417 | Fluorescent antibody test | ~8 days |
| HBV drug resistance mutation [Sequencing] | AC-GCL-K599 | Sanger sequencing | ~11 days |
| HCV 1b NS5A L31/Y93 drug resistance mutation [Sequencing] | AC-GCL-L265 | Sanger sequencing | ~13 days |
| HCV genotype [Real-time PCR] | AC-GCL-N340 | RT-PCR with hybridization | ~10 days |
| HDV RT-PCR | AC-GCL-S752 | RT-PCR | ~14 days |
| Helicobacter pylori [Real-time PCR] | AC-GCL-G302 | Real-time PCR | ~8 days |
| Helicobacter pylori & clarithromycin resistance test | AC-GCL-L641 | Real-time PCR | ~8 days |
| HEV IgG | AC-GCL-S306 | EIA (Enzyme immunoassay) | ~13 days |
| HEV IgM | AC-GCL-S334 | EIA (Enzyme immunoassay) | ~13 days |
| HEV RT-PCR | AC-GCL-B562 | RT-PCR | ~14 days |
| Human herpes virus type 6 [PCR] | AC-GCL-S653 | PCR (Polymerase chain reaction) | ~16 days |
| Human immunodeficiency virus (Quantitative) [Real-time PCR] | AC-GCL-M344 | Real-time RT-PCR | ~12 days |
| Human T cell lymphotropic virus types I and II (HTLV-I/-II) Ab | AC-GCL-S703 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| JC virus PCR | AC-GCL-K085 | PCR (Polymerase chain reaction) | ~10 days |
| Krebs von den Lungen-6 (KL-6) | AC-GCL-P312 | TIA (Turbidimetric immunoassay) | ~9 days |
| Legionella pneumophila [Real-time PCR] | AC-GCL-K080 | Real-time PCR | ~8 days |
| Legionella urinary antigen | AC-GCL-B002 | FIA (Fluorescence immunoassay) | ~9 days |
| Leptospira Ab | AC-GCL-S455 | ICA (Immunochromatographic assay) | ~8 days |
| Leptospira Ab [MAT] | AC-GCL-S792 | MAT (Microscopic agglutination test) | ~8 days |
| Malaria detection & identification [PCR] | AC-GCL-M695 | PCR (Polymerase chain reaction) | ~10 days |
| Malaria P. falciparum | AC-GCL-M696 | PCR (Polymerase chain reaction) | ~10 days |
| Malaria P. malariae | AC-GCL-M698 | PCR (Polymerase chain reaction) | ~10 days |
| Malaria P. ovale | AC-GCL-M699 | PCR (Polymerase chain reaction) | ~10 days |
| Malaria P. vivax | AC-GCL-M697 | PCR (Polymerase chain reaction) | ~10 days |
| Meningitis Pathogen bacteria Panel [Multiplex PCR] | AC-GCL-G090 | Multiplex PCR | ~8 days |
| Modified Hodge testing | AC-GCL-N229 | Disk diffusion | ~10 days |
| MTB & NTM PCR [Others] | AC-GCL-X931 | Real-time PCR | ~10 days |
| MTB & NTM PCR [Sputum] | AC-GCL-F444 | Real-time PCR | ~10 days |
| MTB & NTM PCR [Tissue] | AC-GCL-W789 | Real-time PCR | ~11 days |
| MTB sensitivity | AC-GCL-B124 | Absolute concentration | ~37 days |
| Mycoplasma Ab | AC-GCL-S458 | HA (Hemagglutination) | ~8 days |
| Mycoplasma pneumoniae IgG | AC-GCL-C548 | CIA (Chemiluminescence immunoassay) | ~8 days |
| Mycoplasma pneumoniae IgM | AC-GCL-C549 | CIA (Chemiluminescence immunoassay) | ~8 days |
| NTM sensitivity | AC-GCL-X560 | Microdilution | ~32 days |
| O. tsutsugamushi [Real-time PCR] | AC-GCL-W058 | Real-time PCR | ~10 days |
| O. tsutsugamushi Ab | AC-GCL-S706 | Fluorescent antibody test | ~8 days |
| Paragonimus westermani Ab IgG | AC-GCL-X882 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Parainfluenza virus Ag | AC-GCL-B110 | DIFA (Direct immunofluorescent assay) | ~9 days |
| Parasite specific Ab IgG | AC-GCL-S644 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Parvovirus B19 PCR | AC-GCL-S642 | PCR (Polymerase chain reaction) | ~12 days |
| Pneumocystis jirovecii PCR | AC-GCL-P001 | PCR (Polymerase chain reaction) | ~10 days |
| Polyomavirus PCR | AC-GCL-H171 | PCR (Polymerase chain reaction) | ~10 days |
| Respiratory Pathogen bacteria Panel [Multiplex real-time PCR] | AC-GCL-G290 | Multiplex real-time PCR | ~8 days |
| Respiratory Pathogen virus Panel [Multiplex real-time PCR] | AC-GCL-K453 | Multiplex real-time RT-PCR | ~8 days |
| Respiratory Syncytial Virus Antigen | AC-GCL-B109 | DIFA (Direct immunofluorescent assay) | ~9 days |
| Respiratory virus antigen screening test | AC-GCL-B106 | DIFA (Direct immunofluorescent assay) | ~9 days |
| Rickettsia typhi Ab (murine typhus) | AC-GCL-S793 | Fluorescent antibody test | ~8 days |
| Rubella [RT-PCR] | AC-GCL-S739 | RT-PCR | ~10 days |
| Rubella IgG avidity | AC-GCL-E962 | EIA (Enzyme immunoassay) | ~13 days |
| Salmonella PCR | AC-GCL-Z912 | PCR (Polymerase chain reaction) | ~11 days |
| Screening test for viral meningitis pathogens 7 types PCR | AC-GCL-N797 | Multiplex PCR | ~8 days |
| SFTS [Real-time RT-PCR] | AC-GCL-N989 | Real-time RT-PCR | ~10 days |
| Sparganum Ab IgG | AC-GCL-X884 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| STD 6 type [Multiplex real-time PCR] | AC-GCL-L117 | Multiplex real-time PCR | ~8 days |
| STD 7 types [Multiplex real-time PCR] | AC-GCL-N134 | Multiplex real-time PCR | ~8 days |
| STD STI PCR (13 types) | AC-GCL-L765 | Multiplex real-time PCR | ~8 days |
| Streptococcus pneumoniae antigen [RU] | AC-GCL-B001 | FIA (Fluorescence immunoassay) | ~9 days |
| Toxocara canis Ab, IgG | AC-GCL-S625 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Toxoplasma PCR | AC-GCL-S892 | PCR (Polymerase chain reaction) | ~9 days |
| Trematodes Examination | AC-GCL-H138 | Microscopy | ~8 days |
| Ureaplasma urealyticum [Real-time PCR] | AC-GCL-S934 | Real-time PCR | ~8 days |
| Varicella zoster virus PCR | AC-GCL-Z006 | PCR (Polymerase chain reaction) | ~9 days |
| Zika virus [Real-time RT-PCR] | AC-GCL-L821 | Real-time RT-PCR | ~8 days |
Immunology & HLA
86 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Alzheimer disease biomarkers (2 tests) | AC-GCL-W720 | ECLIA (Electrochemiluminescence immunoassay) & calculation | ~13 days |
| Anti tissue transglutaminase Ab IgA | AC-GCL-P525 | ELISA (Enzyme linked immunosorbent assay) | ~13 days |
| Anti-acetylcholine receptor (AChR) Ab (binding Ab) | AC-GCL-S707 | RRA (Radio receptor assay) | ~10 days |
| Anti-Aquaporin 4 IgG Antibody | AC-GCL-K023 | IFA (Immunofluorescent assay) | ~10 days |
| Anti-cardiolipin Ab, IgA | AC-GCL-S332 | EIA (Enzyme immunoassay) | ~10 days |
| Anti-cardiolipin Ab, IgG | AC-GCL-S494 | EIA (Enzyme immunoassay) | ~9 days |
| Anti-cardiolipin Ab, IgM | AC-GCL-S495 | EIA (Enzyme immunoassay) | ~9 days |
| Anti-centromere Ab | AC-GCL-S981 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Anti-cyclic citrullinated peptide (CCP) Ab | AC-GCL-S610 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| Anti-dsDNA Ab, IgG | AC-GCL-S451 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-dsDNA Ab, IgM | AC-GCL-E685 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Anti-ENA and anti-DNA antibodies multiplex test | AC-GCL-P775 | Line immunoassay (Immunoblot) | ~10 days |
| Anti-ENA and anti-DNA antibodies screening test (Qualitative) | AC-GCL-P469 | EIA (Enzyme immunoassay) | ~9 days |
| Anti-gastric parietal cell Ab | AC-GCL-S518 | Fluorescent antibody test | ~8 days |
| Anti-glomerular basement membrane (GBM) Ab | AC-GCL-S719 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-glutamic acid decarboxylase (GAD) Ab | AC-GCL-S626 | IRMA (Immunoradiometric assay) | ~11 days |
| Anti-GM1 Ab, IgG | AC-GCL-S662 | Line immunoassay (Immunoblot) | ~9 days |
| Anti-GM1 Ab, IgM | AC-GCL-S663 | Line immunoassay (Immunoblot) | ~9 days |
| Anti-histone Ab | AC-GCL-S488 | EIA (Enzyme immunoassay) | ~13 days |
| Anti-insulin Ab | AC-GCL-S958 | RIA (Radioimmunoassay) | ~11 days |
| Anti-Jo-1 Ab | AC-GCL-S125 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-liver/kidney microsome type 1 Ab | AC-GCL-S804 | Fluorescent antibody test | ~10 days |
| Anti-mitochondrial Ab | AC-GCL-S435 | Fluorescent antibody test | ~8 days |
| Anti-MOG antibody [Flow cytometry] | AC-GCL-W759 | Flow cytometry | ~11 days |
| Anti-MPO Ab | AC-GCL-B152 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-neutrophil cytoplasmic Ab (ANCA, Qualitative) | AC-GCL-S924 | Fluorescent antibody test | ~9 days |
| Anti-neutrophil cytoplasmic Ab (ANCA, Quantitative) | AC-GCL-S231 | Fluorescent antibody test | ~9 days |
| Anti-phospholipid Ab, IgG | AC-GCL-S732 | EIA (Enzyme immunoassay) | ~10 days |
| Anti-phospholipid Ab, IgM | AC-GCL-S784 | EIA (Enzyme immunoassay) | ~10 days |
| Anti-PLA2R Ab, IgG | AC-GCL-N641 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Anti-platelet Ab | AC-GCL-H420 | Fluorescent antibody test | ~10 days |
| Anti-PR3 Ab | AC-GCL-B151 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-ribosomal P Ab | AC-GCL-B342 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-RNP Ab | AC-GCL-S513 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-Scl-70 Ab | AC-GCL-S953 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-Sm Ab | AC-GCL-S516 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-smooth muscle Ab | AC-GCL-S439 | Fluorescent antibody test | ~8 days |
| Anti-SS-A/Ro Ab | AC-GCL-S514 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Anti-SS-B/La Ab | AC-GCL-S515 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| ASCA (S. cerevisiae) IgA | AC-GCL-X700 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| ASCA (S. cerevisiae) IgG | AC-GCL-X701 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| ASCA (Saccharomyces Ab) | AC-GCL-S978 | FEIA (Fluorescence enzyme immunoassay) | ~9 days |
| Autoimmune liver disease antibody multiplex test | AC-GCL-P305 | Line immunoassay (Immunoblot) | ~11 days |
| Beta-Amyloid (1-42) | AC-GCL-W722 | ECLIA (Electrochemiluminescence immunoassay) | ~13 days |
| C1 inhibitor (C1 inactivator, C1-esterase inhibitor) | AC-GCL-S999 | NIA (Nephelometric immunoassay) | ~11 days |
| Complement C3 [S] | AC-GCL-S442 | TIA (Turbidimetric immunoassay) | ~8 days |
| Complement C4 [S] | AC-GCL-S443 | TIA (Turbidimetric immunoassay) | ~8 days |
| Complement, Total (CH50) | AC-GCL-S444 | Enzymatic assay | ~8 days |
| Cryoglobulin [S] | AC-GCL-H417 | Cold-induced precipitation | ~10 days |
| Fluorescent anti-nuclear Ab (FANA, Qualitative) | AC-GCL-S452 | Fluorescent antibody test | ~8 days |
| Fluorescent anti-nuclear Ab (FANA, Quantitative) | AC-GCL-S449 | Fluorescent antibody test | ~8 days |
| Ganglioside Ab IgG Panel | AC-GCL-X729 | Line immunoassay (Immunoblot) | ~9 days |
| Ganglioside Ab IgM Panel | AC-GCL-X727 | Line immunoassay (Immunoblot) | ~9 days |
| HLA-A (DNA-High Resolution) | AC-GCL-Z015 | PCR & sequencing | ~18 days |
| HLA-A (DNA-Low Resolution) | AC-GCL-X620 | PCR & sequencing | ~18 days |
| HLA-ABC (DNA-Low Resolution) | AC-GCL-S761 | PCR & sequencing | ~18 days |
| HLA-ABC, DRB1 (DNA-High Resolution) | AC-GCL-N231 | PCR & sequencing | ~18 days |
| HLA-ABC, DRB1 (DNA-Low Resolution) | AC-GCL-N230 | PCR & sequencing | ~18 days |
| HLA-B (DNA-High Resolution) | AC-GCL-Z016 | PCR & sequencing | ~18 days |
| HLA-B (DNA-Low Resolution) | AC-GCL-X567 | PCR & sequencing | ~18 days |
| HLA-B*5801 genotype [Real-time PCR] | AC-GCL-L598 | Real-time PCR | ~15 days |
| HLA-B27 | AC-GCL-S501 | Real-time PCR | ~10 days |
| HLA-B51 | AC-GCL-Z131 | Real-time PCR | ~11 days |
| HLA-C (DNA-High Resolution) | AC-GCL-Z017 | PCR & sequencing | ~18 days |
| HLA-C (DNA-Low Resolution) | AC-GCL-K061 | PCR & sequencing | ~18 days |
| HLA-DQB1 (DNA High Resolution) | AC-GCL-Z160 | PCR & sequencing | ~18 days |
| HLA-DQB1 (DNA Low Resolution) | AC-GCL-Z159 | PCR & sequencing | ~18 days |
| HLA-DRB1 (DNA-High Resolution) | AC-GCL-Z957 | PCR & sequencing | ~18 days |
| HLA-DRB1 (DNA-Low Resolution) | AC-GCL-S754 | PCR & sequencing | ~18 days |
| IgD | AC-GCL-C424 | TIA (Turbidimetric immunoassay) | ~9 days |
| IgG Index (serum + CSF) | AC-GCL-S230 | Calculation | ~8 days |
| IgG Subclass I | AC-GCL-S121 | TIA (Turbidimetric immunoassay) | ~9 days |
| IgG Subclass II | AC-GCL-S122 | TIA (Turbidimetric immunoassay) | ~9 days |
| IgG Subclass III | AC-GCL-S123 | TIA (Turbidimetric immunoassay) | ~9 days |
| IgG Subclass IV | AC-GCL-S124 | TIA (Turbidimetric immunoassay) | ~9 days |
| Immunoglobulin A (IgA) [S] | AC-GCL-C422 | TIA (Turbidimetric immunoassay) | ~8 days |
| Immunoglobulin G (IgG) [CSF] | AC-GCL-S520 | TIA (Turbidimetric immunoassay) | ~8 days |
| Immunoglobulin G (IgG) [S] | AC-GCL-C421 | TIA (Turbidimetric immunoassay) | ~8 days |
| Paraneoplastic Ab | AC-GCL-E414 | Immunoblot assay | ~9 days |
| Phospho-Tau (181P) | AC-GCL-W721 | ECLIA (Electrochemiluminescence immunoassay) | ~13 days |
| PRA ID (Class I) | AC-GCL-M742 | FIA (Fluorescence immunoassay) | ~16 days |
| PRA ID (Class II) | AC-GCL-M743 | FIA (Fluorescence immunoassay) | ~16 days |
| PRA screening (Class I) | AC-GCL-A030 | FIA (Fluorescence immunoassay) | ~16 days |
| PRA screening (Class II) | AC-GCL-M741 | FIA (Fluorescence immunoassay) | ~16 days |
| Rheumatoid factor (Quantitative) | AC-GCL-S112 | TIA (Turbidimetric immunoassay) | ~8 days |
| Soluble IL-2 receptor | AC-GCL-L927 | CIA (Chemiluminescence immunoassay) | ~9 days |
Toxicology & Drug Monitoring
84 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| [OHE] 1,2-Dichloropropane (1,2-DCP) [RU] | AC-GCL-P711 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] Arsenic (As) [RU] | AC-GCL-K527 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~13 days |
| [OHE] Cadmium (Cd) [RU] | AC-GCL-K522 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~13 days |
| [OHE] Cadmium (Cd) [WB] | AC-GCL-P052 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| [OHE] Chromium (Cr) [RU] | AC-GCL-K509 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~13 days |
| [OHE] Indium (In) [S] | AC-GCL-P417 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| [OHE] Lead (Pb) [RU] | AC-GCL-K508 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~13 days |
| [OHE] Lead (Pb) [WB] | AC-GCL-P054 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| [OHE] Mandelic acid + Phenylglyoxilic acid (MA+PGA) [RU] | AC-GCL-W128 | HPLC-UVD (High performance liquid chromatography-UV-detector) | ~11 days |
| [OHE] Mercury (Hg) [RU] | AC-GCL-K526 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| [OHE] Mercury (Hg) [WB] | AC-GCL-K528 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| [OHE] Methyl hippuric acid (MHA) [RU] | AC-GCL-P053 | HPLC-UVD (High performance liquid chromatography-UV-detector) | ~11 days |
| [OHE] Muconic acid (t,t-MA) [RU] | AC-GCL-K517 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~16 days |
| [OHE] N-Methylacetamide (NMAC) [RU] | AC-GCL-P059 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~14 days |
| [OHE] N-Methylformamide (NMF) [RU] | AC-GCL-P058 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~14 days |
| [OHE] Nickel (Ni) [RU] | AC-GCL-L256 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~14 days |
| [OHE] o-Cresol [RU] | AC-GCL-P573 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~12 days |
| [OHE] Phenol [RU] | AC-GCL-K520 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] TCA_1,1,1-TCE [RU] | AC-GCL-P057 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] TCA_PCE [RU] | AC-GCL-P055 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] TCA_TCE [RU] | AC-GCL-P056 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] Total trichloro-ethanol [RU] | AC-GCL-L736 | HS-GC-MS (Headspace-gas chromatography-mass spectrometry) | ~13 days |
| [OHE] Vanadium (V) [RU] | AC-GCL-W129 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~14 days |
| 13 sets of heavy metals & minerals, whole blood | AC-GCL-L941 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~14 days |
| 13 sets of heavy metals & minerals, whole blood (for follow up) | AC-GCL-L942 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~14 days |
| 4 sets of heavy metals, whole blood [ICP-MS] | AC-GCL-L459 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~12 days |
| 40 sets of heavy metals & minerals [Hair, ICP-MS] | AC-GCL-X979 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~14 days |
| Acetaminophen [S] | AC-GCL-D704 | EIA (Enzyme immunoassay) | ~8 days |
| Adequacy test for hemodialysate (trace elements) | AC-GCL-X043 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~19 days |
| Aldolase [S] | AC-GCL-C471 | Enzymatic assay | ~9 days |
| Aluminium [ICP-MS] | AC-GCL-C441 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Amphetamine [RU] | AC-GCL-D419 | TIA (Turbidimetric immunoassay) | ~8 days |
| Anti-infliximab Ab | AC-GCL-P643 | FIA (Fluorescence immunoassay) | ~10 days |
| Arsenic [WB, ICP-MS] | AC-GCL-L575 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Barbiturates [RU] | AC-GCL-D413 | TIA (Turbidimetric immunoassay) | ~8 days |
| Benzodiazepines [RU] | AC-GCL-C885 | TIA (Turbidimetric immunoassay) | ~8 days |
| Cadmium [ICP-MS] | AC-GCL-C442 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Cannabinoids [RU] | AC-GCL-Z928 | TIA (Turbidimetric immunoassay) | ~8 days |
| Carbamazepine [S] | AC-GCL-D401 | TIA (Turbidimetric immunoassay) | ~8 days |
| Ceruloplasmin [S] | AC-GCL-C461 | TIA (Turbidimetric immunoassay) | ~8 days |
| Chromium [ICP-MS] | AC-GCL-C444 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Chromium [WB, ICP-MS] | AC-GCL-W649 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Clozapine/Norclozapine [LC-MS/MS] | AC-GCL-S808 | LC-MS/MS (Liquid chromatography-MS/MS) | ~14 days |
| Cobalt (WB) [ICP-MS] | AC-GCL-W650 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Cobalt [ICP-MS] | AC-GCL-B593 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Cocaine [RU] | AC-GCL-C561 | TIA (Turbidimetric immunoassay) | ~8 days |
| Copper (S) [ICP-MS] | AC-GCL-C445 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~9 days |
| Copper [Tissue, ICP-MS] | AC-GCL-E534 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~15 days |
| Copper [U, ICP-MS] | AC-GCL-C450 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~9 days |
| Cyclosporine | AC-GCL-E511 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| Cyclosporine [LC-MS/MS] | AC-GCL-L539 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Ecstasy [RU] | AC-GCL-C437 | ICA (Immunochromatographic assay) | ~8 days |
| Environmental toxic substances I (heavy metals & cotinine) | AC-GCL-P383 | ICP-MS & LC-MS/MS | ~17 days |
| Everolimus [LC-MS/MS] | AC-GCL-K053 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Heroin [RU] | AC-GCL-C564 | TIA (Turbidimetric immunoassay) | ~8 days |
| Infliximab (Quantitative) | AC-GCL-P147 | FIA (Fluorescence immunoassay) | ~10 days |
| Lead [ICP-MS] | AC-GCL-C451 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Levetiracetam | AC-GCL-K114 | LC-MS/MS (Liquid chromatography-MS/MS) | ~16 days |
| Lithium [AAS] | AC-GCL-C447 | AAS (Atomic absorption spectroscopy) | ~8 days |
| Manganese [ICP-MS] | AC-GCL-C449 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Manganese [WB, ICP-MS] | AC-GCL-N880 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Mercury [ICP-MS] | AC-GCL-C446 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Methamphetamine [RU] | AC-GCL-C563 | TIA (Turbidimetric immunoassay) | ~8 days |
| Molybdenum [S, ICP-MS] | AC-GCL-X618 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Morphine [RU] | AC-GCL-D421 | TIA (Turbidimetric immunoassay) | ~8 days |
| Nickel [S, ICP-MS] | AC-GCL-X521 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~11 days |
| Nicotine and metabolites [RU] | AC-GCL-E603 | CIA (Chemiluminescence immunoassay) | ~9 days |
| Nicotine and metabolites [S] | AC-GCL-E604 | CIA (Chemiluminescence immunoassay) | ~9 days |
| Opiates [RU] | AC-GCL-C562 | TIA (Turbidimetric immunoassay) | ~8 days |
| Paraquat (gramoxone) [HPLC] | AC-GCL-D706 | HPLC (High performance liquid chromatography) | ~14 days |
| Phencyclidine [RU] | AC-GCL-Z128 | TIA (Turbidimetric immunoassay) | ~9 days |
| Phenobarbital [S] | AC-GCL-D405 | TIA (Turbidimetric immunoassay) | ~8 days |
| Phenytoin [S] | AC-GCL-D407 | TIA (Turbidimetric immunoassay) | ~8 days |
| Salicylate [S] | AC-GCL-C850 | Colorimetry | ~8 days |
| Selenium [S, ICP-MS] | AC-GCL-H189 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~9 days |
| Selenium [WB, ICP-MS] | AC-GCL-W651 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Sirolimus [LC-MS/MS] | AC-GCL-C509 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Tacrolimus (FK506) | AC-GCL-B568 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| Tacrolimus (FK506) [LC-MS/MS] | AC-GCL-L538 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| TBPE [RU] | AC-GCL-C700 | Colorimetry | ~8 days |
| Theophylline [S] | AC-GCL-D406 | TIA (Turbidimetric immunoassay) | ~8 days |
| Valproic acid [S] | AC-GCL-D409 | EIA (Enzyme immunoassay) | ~8 days |
| Vancomycin [S] | AC-GCL-C714 | TIA (Turbidimetric immunoassay) | ~8 days |
| Zinc [S, ICP-MS] | AC-GCL-C452 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~9 days |
Endocrine & Metabolic
83 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| 17-alpha-OHP (17-alpha-Hydroxyprogesterone) [DBS] | AC-GCL-N910 | FIA (Fluorescence immunoassay) | ~10 days |
| 17-Hydroxycorticosteroid [24hU] | AC-GCL-C436 | Colorimetry | ~10 days |
| 17-Ketosteroid [24hU] | AC-GCL-C435 | Colorimetry | ~10 days |
| 25-OH Vitamin D2 & D3 [LC-MS/MS] | AC-GCL-K209 | LC-MS/MS (Liquid chromatography-MS/MS) | ~11 days |
| 5-HIAA [24hU, LC-MS/MS] | AC-GCL-C438 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Alpha-1-Antitrypsin [S] | AC-GCL-S450 | TIA (Turbidimetric immunoassay) | ~8 days |
| Alpha-1-Antitrypsin [Stool] | AC-GCL-P298 | TIA (Turbidimetric immunoassay) | ~8 days |
| Alpha-1-Antitrypsin Clearance | AC-GCL-E300 | Calculation | ~8 days |
| Amino acid [CSF, LC-MS/MS] | AC-GCL-SA0A | LC-MS/MS (Liquid chromatography-MS/MS) | ~12 days |
| Amino acid [Other, LC-MS/MS] | AC-GCL-SA04 | LC-MS/MS (Liquid chromatography-MS/MS) | ~12 days |
| Amino acid [P, LC-MS/MS] | AC-GCL-C167 | LC-MS/MS (Liquid chromatography-MS/MS) | ~12 days |
| Amino acid [RU, LC-MS/MS] | AC-GCL-SA03 | LC-MS/MS (Liquid chromatography-MS/MS) | ~12 days |
| Amino acid profile [P] | AC-GCL-IM02 | LC-MS/MS (Liquid chromatography-MS/MS) | ~12 days |
| Amylase isoenzymes [RU] | AC-GCL-C699 | EP (Electrophoresis) | ~14 days |
| Amylase isoenzymes [S] | AC-GCL-C608 | EP (Electrophoresis) | ~14 days |
| Bone alkaline phosphatase [S] | AC-GCL-C547 | CIA (Chemiluminescence immunoassay) | ~9 days |
| C-terminal telopeptides (CTX) | AC-GCL-S641 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Catecholamine, fractionated [24hU, LC-MS/MS] | AC-GCL-N596 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Catecholamines (2 fraction) [24hU] | AC-GCL-N593 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Catecholamines 2 fraction [P] | AC-GCL-GA0B | HPLC (High performance liquid chromatography) | ~10 days |
| Catecholamines 3 fraction [P] | AC-GCL-GA0C | HPLC (High performance liquid chromatography) | ~10 days |
| CDT (carbohydrate deficient transferrin) | AC-GCL-E012 | NIA (Nephelometric immunoassay) | ~11 days |
| Citrate excretion [24hU] | AC-GCL-C505 | UVS (UV spectrophotometry) | ~13 days |
| Citric acid [S] | AC-GCL-C639 | UVS (UV spectrophotometry) | ~13 days |
| Coproporphyrin (Quantitative) [24hU] | AC-GCL-U131 | Colorimetry | ~13 days |
| Cortisol, Free [24hU] | AC-GCL-L961 | CMIA (Chemiluminescence microparticle immunoassay) | ~9 days |
| Daratumumab-specific protein [IFE] | AC-GCL-F490 | IFE (Immune fixation electrophoresis) | ~14 days |
| Deoxypyridinoline (DPD) | AC-GCL-S735 | CIA (Chemiluminescence immunoassay) | ~10 days |
| Dopamine [P] | AC-GCL-C604 | HPLC (High performance liquid chromatography) | ~10 days |
| Epinephrine [P] | AC-GCL-E449 | HPLC (High performance liquid chromatography) | ~10 days |
| Fructosamine | AC-GCL-C406 | Colorimetry | ~8 days |
| Gastrin [CIA] | AC-GCL-L420 | CIA (Chemiluminescence immunoassay) | ~9 days |
| GastroPanel | AC-GCL-W314 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Glycated albumin | AC-GCL-K977 | Enzymatic assay | ~8 days |
| Haptoglobin [S] | AC-GCL-S445 | TIA (Turbidimetric immunoassay) | ~8 days |
| HVA [24hU, LC-MS/MS] | AC-GCL-C301 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| HVA [RU, LC-MS/MS] | AC-GCL-SA0Z | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Immunofixation EP, IgD, IgE [RU] | AC-GCL-X719 | IFE (Immune fixation electrophoresis) | ~10 days |
| Immunofixation EP, IgD, IgE [S] | AC-GCL-X718 | IFE (Immune fixation electrophoresis) | ~10 days |
| Immunofixation EP, IgG, IgA, IgM [RU] | AC-GCL-C841 | IFE (Immune fixation electrophoresis) | ~10 days |
| Immunofixation EP, IgG, IgA, IgM [S] | AC-GCL-C690 | IFE (Immune fixation electrophoresis) | ~10 days |
| Intact parathyroid hormone (PTH) | AC-GCL-E412 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Intact PTH & Calcium | AC-GCL-P568 | Colorimetry & ECLIA | ~8 days |
| Lysosomal storage disease (LSD) screening test [LC-MS/MS] | AC-GCL-N403 | LC-MS/MS (Liquid chromatography-MS/MS) | ~11 days |
| Metanephrine [24hU, LC-MS/MS] | AC-GCL-SA0D | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Metanephrines, 2 fraction [24hU, LC-MS/MS] | AC-GCL-GA0P | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| N-terminal telopeptide (NTx) | AC-GCL-Z003 | CIA (Chemiluminescence immunoassay) | ~10 days |
| Newborn screening test (NST & LSD) | AC-GCL-N800 | LC-MS/MS & FIA | ~11 days |
| Newborn screening test (NST) | AC-GCL-W707 | LC-MS/MS & FIA | ~10 days |
| Norepinephrine [P] | AC-GCL-E450 | HPLC (High performance liquid chromatography) | ~10 days |
| Normetanephrine [24hU, LC-MS/MS] | AC-GCL-SA0C | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Oligoclonal Banding, S and CSF | AC-GCL-C170 | IEF & IF (Isoelectric focusing with immunofixation) | ~12 days |
| Osteocalcin | AC-GCL-K662 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Pancreatic Amylase | AC-GCL-X207 | Colorimetry | ~8 days |
| Porphyrin (Qualitative) [RU] | AC-GCL-U125 | Colorimetry | ~9 days |
| Prealbumin | AC-GCL-B592 | TIA (Turbidimetric immunoassay) | ~8 days |
| Pyruvic acid [WB] | AC-GCL-C506 | Enzymatic assay | ~9 days |
| sFlt-1/PlGF ratio | AC-GCL-N062 | ECLIA & calculation | ~8 days |
| Stone analysis | AC-GCL-C200 | Colorimetry | ~9 days |
| Stone Analysis [FT-IR] | AC-GCL-Z018 | IR (Infrared absorption spectrometry) | ~9 days |
| Synovial Fluid (crystal) | AC-GCL-S795 | Polarizing microscopy | ~8 days |
| T4 (thyroxin) [DBS] | AC-GCL-N912 | FIA (Fluorescence immunoassay) | ~10 days |
| Thyroid-stimulating immunoglobulin (TSI) [S] | AC-GCL-E562 | Bioassay | ~12 days |
| Thyrotropin receptor Ab [S] | AC-GCL-X946 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Thyroxine (T4), Total | AC-GCL-E402 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Total galactose [DBS] | AC-GCL-N911 | FIA (Fluorescence immunoassay) | ~10 days |
| Total Human Chorionic Gonadotropin (hCG), Tumor Marker | AC-GCL-E865 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Total procollagen-type 1 N-terminal propeptide (total P1NP) | AC-GCL-N935 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Triiodothyronine (T3), Total | AC-GCL-E401 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| TSH (thyroid stimulating hormone) [DBS] | AC-GCL-N909 | FIA (Fluorescence immunoassay) | ~10 days |
| Urinary bromide [RU, ICP-MS] | AC-GCL-L042 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Urinary bromide for iodine loading test [24hU, ICP-MS] | AC-GCL-L043 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Urinary iodine [RU, ICP-MS] | AC-GCL-L040 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Urinary iodine for iodine loading test [24hU, ICP-MS] | AC-GCL-L041 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~10 days |
| Urine dopamine (catecholamines, free) [24hU, LC-MS/MS] | AC-GCL-U604 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Urine Epinephrine (2 fraction) [24hU] | AC-GCL-N595 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Urine epinephrine (catecholamines, free) [24hU, LC-MS/MS] | AC-GCL-U449 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Urine Norepinephrine (2 fraction) [24hU] | AC-GCL-N594 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Urine norepinephrine (catecholamines, free) [24hU, LC-MS/MS] | AC-GCL-U450 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
| Uroporphyrin (Qualitative) [RU] | AC-GCL-U122 | Colorimetry | ~14 days |
| Uroporphyrin (Quantitative) [24hU] | AC-GCL-U130 | Colorimetry | ~14 days |
| VMA (Qualitative) | AC-GCL-C433 | Colorimetry | ~8 days |
| VMA (Quantitative) [LC-MS/MS] | AC-GCL-C434 | LC-MS/MS (Liquid chromatography-MS/MS) | ~10 days |
Chemistry & Tumour Markers
66 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Acetylcholinesterase [Amniotic fluid] | AC-GCL-C206 | EP (Electrophoresis) | ~12 days |
| ADAMTS13 activity [ELISA] | AC-GCL-N972 | ELISA (Enzyme linked immunosorbent assay) | ~10 days |
| Adenosine deaminase (ADA) [Other] | AC-GCL-P299 | Enzymatic assay | ~8 days |
| Adenosine deaminase (ADA) [S] | AC-GCL-C512 | Enzymatic assay | ~8 days |
| Alkaline phosphatase, Total and Iso [S] | AC-GCL-C412 | EP (Electrophoresis) | ~15 days |
| Alpha-Fetoprotein (AFP), BF | AC-GCL-E952 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Alpha-Fetoprotein (AFP), Tumor marker | AC-GCL-C409 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Amylase [RU] | AC-GCL-C472 | Colorimetry | ~8 days |
| Amyloid A | AC-GCL-P864 | TIA (Turbidimetric immunoassay) | ~8 days |
| Angiotensin converting enzyme (ACE) | AC-GCL-C511 | Enzymatic assay | ~8 days |
| Apolipoprotein A2 | AC-GCL-S744 | TIA (Turbidimetric immunoassay) | ~8 days |
| Apolipoprotein C2 | AC-GCL-S745 | TIA (Turbidimetric immunoassay) | ~8 days |
| Apolipoprotein C3 | AC-GCL-S743 | TIA (Turbidimetric immunoassay) | ~8 days |
| Apolipoprotein E | AC-GCL-S818 | TIA (Turbidimetric immunoassay) | ~8 days |
| Beta-2-Microglobulin [RU] | AC-GCL-C617 | CIA (Chemiluminescence immunoassay) | ~9 days |
| Beta-2-Microglobulin [S] | AC-GCL-S448 | CIA (Chemiluminescence immunoassay) | ~9 days |
| Bile Acids | AC-GCL-C171 | Enzymatic assay | ~8 days |
| Biological antioxidant potential and Reactive oxygen metabolites | AC-GCL-K091 | Colorimetry | ~8 days |
| CA125 (ROMA, if postmenopausal) | AC-GCL-G282 | ECLIA (Electrochemiluminescence immunoassay) | ~9 days |
| CA125 (ROMA, if premenopausal) | AC-GCL-G279 | ECLIA (Electrochemiluminescence immunoassay) | ~9 days |
| CA125 (ROMA) | AC-GCL-L457 | ECLIA (Electrochemiluminescence immunoassay) | ~9 days |
| Cancer Ag 72-4 (CA 72-4) | AC-GCL-E514 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Carcinoembryonic Ag (CEA) | AC-GCL-C408 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Carcinoembryonic Ag (CEA), BF | AC-GCL-E953 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Chromogranin A | AC-GCL-N132 | ELISA (Enzyme linked immunosorbent assay) | ~13 days |
| CK-BB [S] | AC-GCL-C678 | EP (Electrophoresis) | ~10 days |
| CK-MM [S] | AC-GCL-C674 | EP (Electrophoresis) | ~10 days |
| Creatine kinase isoenzyme reflex [S] | AC-GCL-C413 | EP (Electrophoresis) | ~10 days |
| Cystatin-C | AC-GCL-Z883 | TIA (Turbidimetric immunoassay) | ~8 days |
| Cytokeratin 19 (CYFRA 21-1) | AC-GCL-E602 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| Erythropoietin [S] | AC-GCL-S502 | CIA (Chemiluminescence immunoassay) | ~9 days |
| Free fatty acids (FFA) [S] | AC-GCL-C166 | Colorimetry | ~8 days |
| Free kappa light chain [S] | AC-GCL-Z983 | TIA (Turbidimetric immunoassay) | ~9 days |
| Free kappa light chain [U] | AC-GCL-C181 | TIA (Turbidimetric immunoassay) | ~9 days |
| Free lambda light chain [S] | AC-GCL-Z982 | TIA (Turbidimetric immunoassay) | ~9 days |
| Free lambda light chain [U] | AC-GCL-C182 | TIA (Turbidimetric immunoassay) | ~9 days |
| Free PSA [phi] | AC-GCL-P039 | CIA & calculation | ~9 days |
| Glycosylation isomer of Mac-2 binding protein (M2BPGi) | AC-GCL-N313 | CLEIA (Chemiluminescence enzyme immunoassay) | ~9 days |
| Hemosiderin [RU] | AC-GCL-H431 | Microscopy | ~13 days |
| Lactate dehydrogenase isoenzymes [S] | AC-GCL-C414 | EP (Electrophoresis) | ~10 days |
| Lactate Dehydrogenase Isoenzymes, Others | AC-GCL-C846 | EP (Electrophoresis) | ~10 days |
| LDL particle size | AC-GCL-Z695 | EP (Electrophoresis) | ~10 days |
| Leucine Aminopeptidase (LAP) | AC-GCL-S267 | Enzymatic assay | ~8 days |
| Lipoprotein, Electrophoresis, BF | AC-GCL-C842 | EP (Electrophoresis) | ~14 days |
| N-Acetyl-beta-D-Glucosaminidase (NAG) | AC-GCL-C172 | Colorimetry | ~9 days |
| Neuron specific enolase (NSE) [S] | AC-GCL-S465 | ECLIA (Electrochemiluminescence immunoassay) | ~8 days |
| NGAL (Quantitative) | AC-GCL-P416 | Particle-enhanced turbidimetric immunoassay | ~9 days |
| Nuclear matrix protein 22 (NMP22) | AC-GCL-Z136 | EIA (Enzyme immunoassay) | ~9 days |
| p2PSA [phi] | AC-GCL-P038 | CIA & calculation | ~9 days |
| Pepsinogen I | AC-GCL-E501 | TIA (Turbidimetric immunoassay) | ~8 days |
| Pepsinogen II | AC-GCL-E502 | TIA (Turbidimetric immunoassay) | ~8 days |
| Pepsinogen ratio | AC-GCL-E504 | Calculation | ~8 days |
| phi (prostate health index) | AC-GCL-N727 | CIA & calculation | ~9 days |
| PIVKA 2 (Des-gamma-carboxy prothrombin) | AC-GCL-E525 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| Prostatic acid phosphatase [S] | AC-GCL-C168 | CIA (Chemiluminescence immunoassay) | ~11 days |
| PSA [phi] | AC-GCL-P037 | CIA & calculation | ~9 days |
| Pseudocholinesterase | AC-GCL-C155 | Colorimetry | ~8 days |
| ROMA Score | AC-GCL-L455 | ECLIA & calculation | ~9 days |
| ROMA Score, if postmenopausal | AC-GCL-G281 | ECLIA & calculation | ~9 days |
| ROMA Score, if premenopausal | AC-GCL-G278 | ECLIA & calculation | ~9 days |
| sdLDL cholesterol | AC-GCL-W396 | Colorimetry | ~8 days |
| Selectivity Index (IgG, Transferrin), S and U | AC-GCL-C427 | TIA (Turbidimetric immunoassay) | ~8 days |
| Soluble ST2 | AC-GCL-L631 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| Squamous cell carcinoma (SCC, T4-4) [S] | AC-GCL-S467 | CMIA (Chemiluminescence microparticle immunoassay) | ~8 days |
| Total oxidant and antioxidant status [S] | AC-GCL-N708 | Colorimetry | ~8 days |
| Zinc [U, ICP-MS] | AC-GCL-C459 | ICP-MS (Inductively coupled plasma-mass spectrometry) | ~9 days |
Precision Oncology
47 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| BRAF gene mutation [Real-time PCR] | AC-GCL-M345 | Real-time PCR | ~11 days |
| BRAF gene mutation [Sequencing] | AC-GCL-L446 | PCR & sequencing | ~13 days |
| c-KIT gene mutation [BM, Sequencing] | AC-GCL-N040 | PCR & sequencing | ~23 days |
| c-KIT gene mutation [Tissue, Sequencing] | AC-GCL-X348 | PCR & sequencing | ~18 days |
| c-KIT gene mutation [WB, Sequencing] | AC-GCL-X757 | PCR & sequencing | ~23 days |
| CALR gene mutation [Fragment analysis & Sequencing] | AC-GCL-L535 | Fragment analysis & sequencing | ~19 days |
| CEBPA gene mutation [Sequencing] | AC-GCL-M347 | PCR & sequencing | ~22 days |
| CYP2C19 Major Polymorphism [Real-time PCR] | AC-GCL-M341 | PCR with hybridization | ~13 days |
| CYP2C9 Major Polymorphism [Sequencing] | AC-GCL-M340 | PCR & sequencing | ~13 days |
| EGFR (cell-free DNA) [Real-time PCR] | AC-GCL-N537 | Real-time PCR | ~11 days |
| EGFR [Tissue, Real-time PCR] | AC-GCL-L694 | Real-time PCR | ~11 days |
| FLT3-ITD mutation [Fragment analysis & Sequencing] | AC-GCL-M745 | Fragment analysis & sequencing | ~22 days |
| FLT3-TKD mutation [Sequencing] | AC-GCL-M746 | PCR & sequencing | ~22 days |
| GLA gene mutation (Fabry disease) [Sequencing] | AC-GCL-M019 | PCR & sequencing | ~29 days |
| HLA Typing (6-loci) [NGS] | AC-GCL-W189 | NGS (next generation sequencing) | ~26 days |
| IGH gene rearrangement (WB/BM) | AC-GCL-P798 | PCR fragment analysis | ~18 days |
| IGH gene rearrangement [Tissue] | AC-GCL-L020 | PCR fragment analysis | ~18 days |
| JAK2 gene Exon 12 mutation [Sequencing] | AC-GCL-M049 | PCR & sequencing | ~15 days |
| JAK2 V617F mutation [Real-time PCR] | AC-GCL-Z041 | Allele-specific PCR | ~12 days |
| KRAS gene mutation [Sequencing] | AC-GCL-M562 | PCR & sequencing | ~13 days |
| MPL gene W515 mutation [Sequencing] | AC-GCL-L665 | PCR & sequencing | ~19 days |
| MPN gene mutations (JAK2 V617F/Exon 12, CALR, MPL W515K/L) | AC-GCL-M333 | PCR & sequencing | ~19 days |
| MSI (Microsatellite Instability) | AC-GCL-K470 | PCR fragment analysis | ~13 days |
| NOTCH3 gene mutation (CADASIL) [Sequencing] | AC-GCL-Z226 | PCR & sequencing | ~22 days |
| NOTCH3 gene, familial mutation (CADASIL) [Sequencing] | AC-GCL-P538 | PCR & sequencing | ~14 days |
| NPM1 gene mutation [Sequencing] | AC-GCL-M346 | PCR & sequencing | ~15 days |
| NRAS gene mutation [Sequencing] | AC-GCL-M029 | PCR & sequencing | ~13 days |
| NUDT15 genotype [Sequencing] | AC-GCL-N955 | PCR & sequencing | ~22 days |
| PDGFRA gene mutation [Sequencing] | AC-GCL-L025 | PCR & sequencing | ~18 days |
| PIK3CA (cell-free DNA) [Real-time PCR] | AC-GCL-P871 | Real-time PCR | ~22 days |
| PIK3CA [Tissue, Real-time PCR] | AC-GCL-P872 | Real-time PCR | ~22 days |
| Post-SCT (Stem Cell Transplantation) engraftment analysis | AC-GCL-M678 | PCR fragment analysis | ~19 days |
| Pre-SCT (Stem Cell Transplantation) | AC-GCL-M677 | PCR fragment analysis | ~19 days |
| RNF213 gene R4810K mutation (Moyamoya disease) [Sequencing] | AC-GCL-L002 | PCR & sequencing | ~15 days |
| SCA 1 gene mutation (Spinocerebellar ataxia 1) | AC-GCL-Z906 | PCR fragment analysis | ~22 days |
| SCA 1,2,3,6,7 | AC-GCL-N232 | PCR fragment analysis | ~22 days |
| SCA 2 gene mutation (Spinocerebellar ataxia 2) | AC-GCL-Z907 | PCR fragment analysis | ~22 days |
| SCA 3 gene mutation (Spinocerebellar ataxia 3) | AC-GCL-Z908 | PCR fragment analysis | ~22 days |
| SCA 6 gene mutation (Spinocerebellar ataxia 6) | AC-GCL-Z909 | PCR fragment analysis | ~22 days |
| SCA 7 gene mutation (Spinocerebellar ataxia 7) | AC-GCL-Z910 | PCR fragment analysis | ~22 days |
| SRY gene (Sex determining Region Y) [PCR] | AC-GCL-S160 | PCR (Polymerase chain reaction) | ~15 days |
| TCR gamma gene rearrangement (WB/BM) | AC-GCL-P799 | PCR fragment analysis | ~18 days |
| TCR gamma gene rearrangement [Tissue] | AC-GCL-L023 | PCR fragment analysis | ~18 days |
| TERT gene promoter mutation [Real-time PCR] | AC-GCL-N956 | Real-time PCR | ~17 days |
| TPMT Major Polymorphism [Sequencing] | AC-GCL-S233 | PCR & sequencing | ~18 days |
| TTR gene mutation (Hereditary Transthyretin Amyloidosis) [Sequencing] | AC-GCL-N131 | PCR & sequencing | ~23 days |
| UGT1A1 gene mutation (Crigler-Najjar syndrome) [Sequencing] | AC-GCL-N476 | PCR & sequencing | ~22 days |
Allergy & Intolerance
17 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| EDN (eosinophil derived neurotoxin) | AC-GCL-Q620 | ELISA (Enzyme linked immunosorbent assay) | ~13 days |
| Eosinophil cationic protein (ECP) | AC-GCL-S600 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| IgG4 food intolerance 90 | AC-GCL-Q484 | ELISA (Enzyme linked immunosorbent assay) | ~9 days |
| MAST allergy (161-allergen) | AC-GCL-F506 | Line immunoassay (Immunoblot) | ~8 days |
| Specific IgE 12-allergen food panel (children) | AC-GCL-W923 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 6-allergen asthma/rhinitis/dermatitis panel (adults) | AC-GCL-W928 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 6-allergen asthma/rhinitis/dermatitis panel (children) | AC-GCL-W927 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 6-allergen atopy panel | AC-GCL-W926 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 6-allergen food panel 1 (adults) | AC-GCL-W924 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 6-allergen food panel 2 (adults) | AC-GCL-W925 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE 9-allergen anaphylaxis panel (children) | AC-GCL-W941 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| Specific IgE, single allergen | AC-GCL-IGE-SINGLE | FEIA | ~8 days |
| Specific IgG F79 (gluten) | AC-GCL-K489 | FEIA (Fluorescence enzyme immunoassay) | ~10 days |
| Specific IgG4, single food | AC-GCL-IGG4-SINGLE | FEIA | ~9 days |
| Tryptase | AC-GCL-S538 | FEIA (Fluorescence enzyme immunoassay) | ~10 days |
| UniCAP Phadiatop | AC-GCL-I577 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
| UniCAP Phadiatop Infant | AC-GCL-I184 | FEIA (Fluorescence enzyme immunoassay) | ~8 days |
164 assays
GeneDx
Clinical areas AC can route to GeneDx, grouped as the laboratory organises them.
Neurology & Neuromuscular
60 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| ACADVL Gene Analysis in Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency | AC-GDX-270 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Amyotrophic Lateral Sclerosis / Frontotemporal Lobar Degeneration Panel | AC-GDX-T404 | — | ~30 days |
| Angelman Syndrome / Prader-Willi Syndrome Methylation Analysis | AC-GDX-TJ27 | — | ~30 days |
| AR Repeat Analysis | AC-GDX-820 | PCR Fragment Analysis | ~30 days |
| Arthrogryposis Panel | AC-GDX-TG80 | — | ~30 days |
| Ataxia Xpanded Panel | AC-GDX-J762 | Next-Gen Sequencing | ~30 days |
| Autism/ID Panel | AC-GDX-T395 | — | ~30 days |
| Autism/ID Xpanded Panel | AC-GDX-952 | Next-Gen Sequencing | ~45 days |
| C9ORF72 Repeat Analysis | AC-GDX-J805 | PCR Fragment Analysis | ~30 days |
| Cerebral Cavernous Malformations (CCM) Panel | AC-GDX-526 | Capillary Sequencing Deletion/Duplication Analysis | ~30 days |
| CNBP Repeat Analysis | AC-GDX-819 | PCR Fragment Analysis | ~30 days |
| Combined Mito Genome Plus Mito Nuclear Gene Panel | AC-GDX-615 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Comprehensive Brain Malformations Panel | AC-GDX-691 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Comprehensive Epilepsy Panel | AC-GDX-523 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Congenital Hypotonia Xpanded Panel | AC-GDX-TG77 | — | ~30 days |
| Creatine Deficiency Syndromes Panel | AC-GDX-J976 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Dementia Panel | AC-GDX-T844 | — | ~30 days |
| Dentatorubral-Pallidoluysian Atrophy Repeat Analysis | AC-GDX-TH97 | — | ~30 days |
| DMPK Repeat Analysis | AC-GDX-818 | PCR Fragment Analysis | ~30 days |
| Dosage Analysis of SMN1 and SMN2 | AC-GDX-T789 | — | ~30 days |
| Duchenne/Becker MD (DMD) Gene Sequencing & Del/Dup | AC-GDX-GD1007 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Dystonia Panel | AC-GDX-T403 | — | ~30 days |
| Dystonia/Parkinson Panel | AC-GDX-T402 | — | ~30 days |
| EpiXpanded Panel | AC-GDX-921 | Next-Gen Sequencing | ~30 days |
| FMR1 CGG Repeat Analysis | AC-GDX-522 | PCR Fragment Analysis | ~30 days |
| Friedreich Ataxia Repeat Analysis | AC-GDX-TH95 | — | ~30 days |
| Friedreich Ataxia Sequencing and Del/Dup | AC-GDX-TH94 | — | ~30 days |
| Hemiplegic Migraine Panel | AC-GDX-T400 | — | ~30 days |
| Hereditary Neuropathy Sequencing & Del/Dup Panel | AC-GDX-737 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| IDS Sequencing Del/Dup | AC-GDX-T387 | — | ~30 days |
| IKBKG (NEMO) Gene Sequencing & Del/Dup | AC-GDX-553 | Capillary Sequencing Long Range PCR | ~30 days |
| L1CAM Gene Sequencing & Del/Dup | AC-GDX-552 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Leukodystrophy Xpanded Panel | AC-GDX-J853 | Next-Gen Sequencing | ~30 days |
| Leukodystrophy Xpanded, Family Member Testing | AC-GDX-J854 | Next-Gen Sequencing | ~30 days |
| Metabolic Myopathy Panel | AC-GDX-T012 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Microcephaly Xpanded Panel | AC-GDX-J511 | Next-Gen Sequencing | ~30 days |
| Mito Genome Sequencing & Deletion Testing | AC-GDX-554 | Next-Gen Sequencing | ~30 days |
| Mosaic Carrier Testing by NGS | AC-GDX-J829 | Next-Gen Sequencing | ~30 days |
| Myotonia Panel | AC-GDX-TG82 | — | ~30 days |
| Neurofibromatosis (NF1, SPRED1) Panel | AC-GDX-962 | Deletion/Duplication Analysis MLPA Next-Gen Sequencing | ~30 days |
| Neurofibromatosis (NF2) Panel | AC-GDX-963 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Neuromuscular Disorders Panel | AC-GDX-889 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| PABPN1 Repeat Analysis | AC-GDX-743 | Capillary Sequencing | ~30 days |
| Parkinson Disease Panel | AC-GDX-T401 | — | ~30 days |
| Periodic Paralysis Panel | AC-GDX-TG81 | — | ~30 days |
| PMP22 Del/Dup | AC-GDX-742 | Deletion/Duplication Analysis | ~30 days |
| Rett/Angelman & Related Disorders Panel | AC-GDX-729 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Spinocerebellar Ataxia and Related Disorders | AC-GDX-TL12 | — | ~30 days |
| Spinocerebellar Ataxia Repeat Expansion Analysis | AC-GDX-TH83 | — | ~30 days |
| Spinocerebellar Ataxia Type 1 Repeat Analysis | AC-GDX-TH84 | — | ~30 days |
| Spinocerebellar Ataxia Type 2 Repeat Analysis | AC-GDX-TH85 | — | ~30 days |
| Spinocerebellar Ataxia Type 3 Repeat Analysis | AC-GDX-TH86 | — | ~30 days |
| Spinocerebellar Ataxia Type 6 Repeat Analysis | AC-GDX-TH87 | — | ~30 days |
| Spinocerebellar Ataxia Type 7 Repeat Analysis | AC-GDX-TH88 | — | ~30 days |
| Spinocerebellar Ataxia Type 8 Repeat Analysis | AC-GDX-TH89 | — | ~30 days |
| Targeted Variant Analysis of the Mitochondrial DNA (mtDNA) | AC-GDX-453 | Next-Gen Sequencing | ~30 days |
| Testing for 1 to 3 mtDNA Variants w/Heteroplasmy Level - Urine | AC-GDX-T822 | — | ~30 days |
| Tuberous Sclerosis Panel | AC-GDX-730 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| X-Linked Adrenoleukodystrophy | AC-GDX-J975 | Capillary Sequencing MLPA | ~30 days |
| Xpanded Adult Movement Disorders Panel | AC-GDX-TK79 | — | ~30 days |
Specialty Genetics
38 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| ACADM Gene Sequencing | AC-GDX-2682 | — | ~30 days |
| Alport Syndrome Panel | AC-GDX-TG21 | — | ~30 days |
| ASPA Gene Sequencing & Del/Dup | AC-GDX-564 | — | ~30 days |
| ATP7B Gene Sequencing & Del/Dup | AC-GDX-TG92 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Autoimmune Lymphoproliferative Syndrome Panel | AC-GDX-T990 | — | ~30 days |
| Autosomal Dominant Osteogenesis Imperfecta Panel | AC-GDX-T992 | — | ~30 days |
| Cataract Panel | AC-GDX-J958 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| CFTR Sequencing and Deletion/Duplication Analysis | AC-GDX-T829 | — | ~30 days |
| Chronic Granulomatous Disease Panel | AC-GDX-T989 | — | ~30 days |
| Craniosynostosis Panel | AC-GDX-TA40 | — | ~30 days |
| Cystic Kidney and Liver Diseases Panel | AC-GDX-TG23 | — | ~30 days |
| DFNB1 Autosomal Recessive Hearing Loss (GJB2 and common GJB6 deletions) | AC-GDX-TA49 | — | ~30 days |
| Dyskeratosis Congenita Panel | AC-GDX-TB47 | — | ~30 days |
| GAA Gene Sequencing & Del/Dup | AC-GDX-TH08 | Capillary Sequencing Deletion/Duplication Analysis | ~30 days |
| GALT Gene Sequencing & Del/Dup | AC-GDX-349E | — | ~30 days |
| GBA Sequencing Test | AC-GDX-TG94 | Capillary Sequencing | ~30 days |
| Hearing Loss Test | AC-GDX-J806 | Deletion/Duplication Analysis Long Range PCR Next-Gen Sequencing Sanger/ABI sequencing | ~30 days |
| Hypogonadotrophic Hypogonadism Panel | AC-GDX-676 | — | ~30 days |
| Hypokalemia and Related Disorders Panel | AC-GDX-TG98 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Leber Hereditary Optic Neuropathy (LHON) Panel | AC-GDX-TH12 | Next-Gen Sequencing | ~30 days |
| Limb Abnormalities and Reduction Defects Panel | AC-GDX-TA42 | — | ~30 days |
| Maturity-Onset Diabetes of the Young (MODY) Panel | AC-GDX-674 | — | ~30 days |
| Nephrolithiasis and Nephrocalcinosis Panel | AC-GDX-TH01 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Nephrotic Syndrome / Focal Segmental Glomerulosclerosis Syndrome | AC-GDX-TG99 | Capillary Sequencing Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Osteogenesis Imperfecta Panel | AC-GDX-J797 | — | ~30 days |
| PAH Gene Sequencing | AC-GDX-273 | — | ~30 days |
| Periodic Fever Syndromes Panel (7 genes) | AC-GDX-367 | — | ~30 days |
| Polycystic Kidney Disease Seq and Del/Dup Panel | AC-GDX-TG22 | — | ~30 days |
| Premature Ovarian Failure Sequencing Panel | AC-GDX-677 | — | ~30 days |
| Primary Ciliary Dyskinesia | AC-GDX-TB46 | — | ~30 days |
| Primary Hyperoxaluria Panel | AC-GDX-TG90 | — | ~30 days |
| SBDS Gene Sequencing | AC-GDX-109 | — | ~30 days |
| Severe Congenital Neutropenia, Autosomal Dominant (ELANE aka ELA2) | AC-GDX-TA48 | — | ~30 days |
| Skeletal Dysplasia | AC-GDX-TA43 | — | ~30 days |
| SLC22A5 Gene Sequencing | AC-GDX-365 | — | ~30 days |
| Stargardt Panel | AC-GDX-TG49 | — | ~30 days |
| TERC Gene Sequencing | AC-GDX-107 | — | ~30 days |
| Waardenburg Syndrome Panel | AC-GDX-TL50 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
Rare Disease
30 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Congenital Ichthyosis Slice | AC-GDX-708 | — | ~21 days |
| Custom ExonArrayDx | AC-GDX-703 | — | ~30 days |
| Custom Slice (2-150 Genes) | AC-GDX-706 | — | ~21 days |
| Custom Slice (Single Gene) | AC-GDX-TG70 | — | ~21 days |
| Custom Slice Xpanded (>150 Genes) | AC-GDX-J757 | — | ~21 days |
| Epidermolysis Bullosa (EB) Slice | AC-GDX-707 | — | ~21 days |
| Exome Family Member Report (No Charge) | AC-GDX-J962 | — | ~21 days |
| Exome Family Member Report Only | AC-GDX-749 | — | ~21 days |
| Exome-to-Genome Reflex (Exome Interpretation) + Exome-to-Genome Reflex (Genome Interpretation), duo | AC-GDX-GD1009E-GD1010 | — | ~30 days |
| Exome-to-Genome Reflex (Exome Interpretation) + Exome-to-Genome Reflex (Genome Interpretation), proband | AC-GDX-GD1009B-GD1010 | — | ~30 days |
| Exome-to-Genome Reflex (Exome Interpretation) + Exome-to-Genome Reflex (Genome Interpretation), trio | AC-GDX-GD1009A-GD1010 | — | ~30 days |
| Exome-to-Genome Reflex, duo (Exome Interpretation) | AC-GDX-GD1009E | — | ~30 days |
| Exome-to-Genome Reflex, proband (Exome Interpretation) | AC-GDX-GD1009B | — | ~30 days |
| Exome-to-Genome Reflex, trio (Exome Interpretation) | AC-GDX-GD1009A | — | ~30 days |
| ExomeDx + mito, duo | AC-GDX-561E-561M | — | ~21 days |
| ExomeDx + mito, proband | AC-GDX-561B-561M | — | ~21 days |
| ExomeDx + mito, trio | AC-GDX-561A-561M | — | ~21 days |
| ExomeDx Rapid, duo | AC-GDX-896E | — | ~10 days |
| ExomeDx Rapid, proband | AC-GDX-896B | — | ~10 days |
| ExomeDx Rapid, trio | AC-GDX-896A | — | ~10 days |
| ExomeDx, trio | AC-GDX-561A | — | ~21 days |
| GenomeDx Rapid, duo | AC-GDX-TH78E | — | ~10 days |
| GenomeDx Rapid, trio | AC-GDX-TH78A | — | ~10 days |
| GenomeDx Reanalysis, proband | AC-GDX-TG73 | — | ~7 days |
| GenomeDx, duo | AC-GDX-J774E | — | ~30 days |
| GenomeDx, trio | AC-GDX-J774A | — | ~30 days |
| Mutation Confirmation 4+ Variants | AC-GDX-9018 | — | ~30 days |
| Research Del/Dup Confirmation x1 (Institutional Bill or Self-Pay Only) | AC-GDX-TJ34 | — | ~30 days |
| Subsequent ExomeDx Reanalysis, proband | AC-GDX-947 | — | ~21 days |
| Subsequent GenomeDx Reanalysis, proband | AC-GDX-TG72 | — | ~30 days |
Prenatal & NIPT
16 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| ExomeDx Prenatal, duo | AC-GDX-TK89E | — | ~21 days |
| ExomeDx Prenatal, targeted | AC-GDX-959 | — | ~21 days |
| ExomeDx Prenatal, trio | AC-GDX-TK89A | — | ~21 days |
| GenomeDx Prenatal, duo | AC-GDX-GD1008E | — | ~30 days |
| GenomeDx Prenatal, proband | AC-GDX-GD1008B | — | ~30 days |
| GenomeDx Prenatal, trio | AC-GDX-GD1008A | — | ~30 days |
| Maternal Cell Contamination Analysis | AC-GDX-9023 | — | ~30 days |
| Prenatal Akinesia/Arthrogryposis Panel | AC-GDX-TG85 | — | ~30 days |
| Prenatal DMPK Repeat Analysis | AC-GDX-TG16 | — | ~30 days |
| Prenatal FMR1 CGG Repeat Analysis | AC-GDX-TF32 | — | ~30 days |
| Prenatal Joubert Syndrome and Related Disorders Panel | AC-GDX-J803 | — | ~30 days |
| Prenatal Noonan Spectrum Disorders Panel | AC-GDX-357 | — | ~30 days |
| Prenatal Skeletal Dysplasia Panel | AC-GDX-949 | — | ~30 days |
| Prenatal SMN1/SMN2 | AC-GDX-TF33 | — | ~30 days |
| Prenatal Targeted Mutation Analysis (Including Maternal Cell Contamination) | AC-GDX-902 | — | ~30 days |
| Prenatal Tuberous Sclerosis Panel | AC-GDX-934 | — | ~30 days |
Cardiology
14 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Arrhythmia Panel | AC-GDX-695 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Brugada Syndrome (BrS) Panel | AC-GDX-481 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Combined Cardiac Panel (Institutional Bill or Self-Pay Only) | AC-GDX-935 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Ehlers Danlos Panel | AC-GDX-T998 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Familial Hypercholesterolemia (FH) Panel | AC-GDX-J556 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| FBN1 Gene Sequencing & Del/Dup | AC-GDX-918 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Hereditary Hemorrhagic Telangiectasia Panel | AC-GDX-697 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Heritable Disorders of Connective Tissue (HDCT) Panel | AC-GDX-J555 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| LQTS Panel | AC-GDX-727 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Marfan/TAAD & Related Disorders Panel | AC-GDX-883 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Noonan and Comprehensive RASopathies Panel | AC-GDX-TA06 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Rest of Marfan/TAAD Sequencing & Del/Dup Panel if test #918 is negative | AC-GDX-919 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| SCA Arrhythmia Panel | AC-GDX-J552 | Deletion/Duplication Analysis Next-Gen Sequencing | ~30 days |
| Xpanded Congenital Heart Defects Panel | AC-GDX-TJ07 | Next-Gen Sequencing | ~30 days |
Reproductive / Chromosomal
6 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Chromosomal Microarray (MicroarrayDx) | AC-GDX-910 | — | ~30 days |
| Del/Dup for 1 Gene | AC-GDX-906 | — | ~30 days |
| Known Familial Copy Number Variant(s) | AC-GDX-905 | — | ~30 days |
| Prenatal Whole Genome Chromosomal Microarray | AC-GDX-460-PRENATAL | Whole Genome Chromosomal Microarray | ~30 days |
| Two Known Familial Variant in a Nuclear Gene | AC-GDX-9012 | — | ~30 days |
| Whole Genome Array, Products of Conception (POC) | AC-GDX-460-POC | — | ~30 days |
2 assays
3billion
Clinical areas AC can route to 3billion, grouped as the laboratory organises them.
Rare Disease
2 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| 3B-NEO-WES, Basic | AC-RD-NEOB-3B | NGS | ~21 days |
| 3B-NEO-WGS, Premium | AC-RD-NEOP-3B | NGS | ~21 days |
1 assays
GC Genome
Clinical areas AC can route to GC Genome, grouped as the laboratory organises them.
Rare Disease
1 assays
| Assay | Code | Method | TAT |
|---|---|---|---|
| Chromosomal Microarray - GCG | AC-RD-CMA-GCG | — | — |
Turnaround times are the laboratory’s standard processing figures and exclude shipping and local handling. Availability, specimen requirements, and pricing are confirmed per request. Test names are the performing laboratory’s own.
Get in touch
Start with the clinical question
Whether you need a specific assay, a send-out pathway, or help choosing between testing options, AC can help translate the case into the right next step.
Suite 403, 133 Madina Munawara St, Amman, Jordan
+962 791 707 606 info@advancedconsensus.comMessage us on WhatsAppFor website inquiries, do not include patient names, medical record numbers (MRNs), national IDs, dates of birth, or identifiable reports or documents. Secure document exchange should happen through approved clinical channels.